Which has preferable earnings and valuation, MEDP or RMD?

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 6.83 $451.12M $17.06 36.29 ResMed $5.65B 6.01 $1.52B $10.43 22.60

Is MEDP or RMD more profitable?

ResMed has a net margin of 26.94% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.67% 110.15% 24.84% ResMed 26.94% 25.58% 18.89%

Does the media prefer MEDP or RMD?

In the previous week, Medpace had 5 more articles in the media than ResMed. MarketBeat recorded 41 mentions for Medpace and 36 mentions for ResMed. ResMed's average media sentiment score of 1.34 beat Medpace's score of 0.98 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 28 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 28 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EHC or RMD more profitable?

ResMed has a net margin of 26.94% compared to Encompass Health's net margin of 10.01%. ResMed's return on equity of 25.58% beat Encompass Health's return on equity. Company Net Margins Return on Equity Return on Assets Encompass Health 10.01% 18.08% 8.22% ResMed 26.94% 25.58% 18.89%

Does the media prefer EHC or RMD?

In the previous week, ResMed had 11 more articles in the media than Encompass Health. MarketBeat recorded 36 mentions for ResMed and 25 mentions for Encompass Health. ResMed's average media sentiment score of 1.34 beat Encompass Health's score of 1.06 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Encompass Health 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 28 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, HIMS or RMD?

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.35B 2.97 $128.37M -$0.63 N/A ResMed $5.65B 6.01 $1.52B $10.43 22.60

Is HIMS or RMD more profitable?

ResMed has a net margin of 26.94% compared to Hims & Hers Health's net margin of -5.51%. ResMed's return on equity of 25.58% beat Hims & Hers Health's return on equity. Company Net Margins Return on Equity Return on Assets Hims & Hers Health -5.51% -6.51% -1.20% ResMed 26.94% 25.58% 18.89%

Does the media prefer HIMS or RMD?

In the previous week, ResMed had 2 more articles in the media than Hims & Hers Health. MarketBeat recorded 36 mentions for ResMed and 34 mentions for Hims & Hers Health. ResMed's average media sentiment score of 1.34 beat Hims & Hers Health's score of 0.29 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 7 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral ResMed 28 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, RMD or SYK?

Stryker has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.65B 6.01 $1.52B $10.43 22.60 Stryker $25.12B 5.04 $3.25B $9.65 34.21

Is RMD or SYK more profitable?

ResMed has a net margin of 26.94% compared to Stryker's net margin of 14.43%. ResMed's return on equity of 25.58% beat Stryker's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 26.94% 25.58% 18.89% Stryker 14.43% 23.63% 11.39%

Does the media prefer RMD or SYK?

In the previous week, Stryker had 39 more articles in the media than ResMed. MarketBeat recorded 75 mentions for Stryker and 36 mentions for ResMed. Stryker's average media sentiment score of 1.54 beat ResMed's score of 1.34 indicating that Stryker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 28 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stryker 70 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation & earnings, MDT or RMD?

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medtronic $36.36B 3.24 $4.80B $3.73 24.71 ResMed $5.65B 6.01 $1.52B $10.43 22.60

Is MDT or RMD more profitable?

ResMed has a net margin of 26.94% compared to Medtronic's net margin of 13.20%. ResMed's return on equity of 25.58% beat Medtronic's return on equity. Company Net Margins Return on Equity Return on Assets Medtronic 13.20% 14.51% 7.76% ResMed 26.94% 25.58% 18.89%

Does the media favor MDT or RMD?

In the previous week, Medtronic had 9 more articles in the media than ResMed. MarketBeat recorded 45 mentions for Medtronic and 36 mentions for ResMed. Medtronic's average media sentiment score of 1.36 beat ResMed's score of 1.34 indicating that Medtronic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medtronic 35 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 28 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ResMed (RMD) Competitors

$235.73 -0.86 (-0.36%)

As of 03:58 PM Eastern

Compare

RMD vs. MEDP, EHC, HIMS, SYK, and MDT

Should you buy ResMed stock or one of its competitors? ResMed's main competitors and comparable companies include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Stryker (SYK), and Medtronic (MDT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does ResMed compare to Medpace?

Medpace (NASDAQ:MEDP) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

ResMed has a net margin of 26.94% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
ResMed	26.94%	25.58%	18.89%

In the previous week, Medpace had 5 more articles in the media than ResMed. MarketBeat recorded 41 mentions for Medpace and 36 mentions for ResMed. ResMed's average media sentiment score of 1.34 beat Medpace's score of 0.98 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	28 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	28 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.83	$451.12M	$17.06	36.29
ResMed	$5.65B	6.01	$1.52B	$10.43	22.60

78.0% of Medpace shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Medpace presently has a consensus target price of $584.18, indicating a potential downside of 5.63%. ResMed has a consensus target price of $239.38, indicating a potential upside of 1.55%. Given ResMed's stronger consensus rating and higher probable upside, analysts clearly believe ResMed is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
ResMed	0 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.41

Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, ResMed has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Summary

Medpace beats ResMed on 9 of the 16 factors compared between the two stocks.

How does ResMed compare to Encompass Health?

Encompass Health (NYSE:EHC) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

ResMed has lower revenue, but higher earnings than Encompass Health. Encompass Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Encompass Health	$5.94B	2.01	$566.20M	$6.14	19.68
ResMed	$5.65B	6.01	$1.52B	$10.43	22.60

Encompass Health has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, ResMed has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Encompass Health pays an annual dividend of $0.76 per share and has a dividend yield of 0.6%. ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. Encompass Health pays out 12.4% of its earnings in the form of a dividend. ResMed pays out 25.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Encompass Health has raised its dividend for 2 consecutive years and ResMed has raised its dividend for 13 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

97.3% of Encompass Health shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 1.8% of Encompass Health shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, ResMed had 11 more articles in the media than Encompass Health. MarketBeat recorded 36 mentions for ResMed and 25 mentions for Encompass Health. ResMed's average media sentiment score of 1.34 beat Encompass Health's score of 1.06 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Encompass Health	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	28 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Encompass Health currently has a consensus price target of $148.71, indicating a potential upside of 23.05%. ResMed has a consensus price target of $239.38, indicating a potential upside of 1.55%. Given Encompass Health's stronger consensus rating and higher probable upside, analysts plainly believe Encompass Health is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
ResMed	0 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.41

ResMed has a net margin of 26.94% compared to Encompass Health's net margin of 10.01%. ResMed's return on equity of 25.58% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Encompass Health	10.01%	18.08%	8.22%
ResMed	26.94%	25.58%	18.89%

Summary

ResMed beats Encompass Health on 12 of the 19 factors compared between the two stocks.

How does ResMed compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and ResMed (NYSE:RMD) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Hims & Hers Health has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market. Comparatively, ResMed has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Hims & Hers Health currently has a consensus price target of $32.50, suggesting a potential upside of 8.80%. ResMed has a consensus price target of $239.38, suggesting a potential upside of 1.55%. Given Hims & Hers Health's higher probable upside, research analysts clearly believe Hims & Hers Health is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19
ResMed	0 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.41

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 0.7% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.97	$128.37M	-$0.63	N/A
ResMed	$5.65B	6.01	$1.52B	$10.43	22.60

In the previous week, ResMed had 2 more articles in the media than Hims & Hers Health. MarketBeat recorded 36 mentions for ResMed and 34 mentions for Hims & Hers Health. ResMed's average media sentiment score of 1.34 beat Hims & Hers Health's score of 0.29 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	7 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral
ResMed	28 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ResMed has a net margin of 26.94% compared to Hims & Hers Health's net margin of -5.51%. ResMed's return on equity of 25.58% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-5.51%	-6.51%	-1.20%
ResMed	26.94%	25.58%	18.89%

Summary

ResMed beats Hims & Hers Health on 12 of the 16 factors compared between the two stocks.

How does ResMed compare to Stryker?

ResMed (NYSE:RMD) and Stryker (NYSE:SYK) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

In the previous week, Stryker had 39 more articles in the media than ResMed. MarketBeat recorded 75 mentions for Stryker and 36 mentions for ResMed. Stryker's average media sentiment score of 1.54 beat ResMed's score of 1.34 indicating that Stryker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	28 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stryker	70 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ResMed has a net margin of 26.94% compared to Stryker's net margin of 14.43%. ResMed's return on equity of 25.58% beat Stryker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	26.94%	25.58%	18.89%
Stryker	14.43%	23.63%	11.39%

Stryker has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.65B	6.01	$1.52B	$10.43	22.60
Stryker	$25.12B	5.04	$3.25B	$9.65	34.21

ResMed currently has a consensus target price of $239.38, suggesting a potential upside of 1.55%. Stryker has a consensus target price of $386.28, suggesting a potential upside of 17.03%. Given Stryker's stronger consensus rating and higher possible upside, analysts plainly believe Stryker is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.41
Stryker	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.79

55.0% of ResMed shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ResMed has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Stryker has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. Stryker pays an annual dividend of $3.52 per share and has a dividend yield of 1.1%. ResMed pays out 25.3% of its earnings in the form of a dividend. Stryker pays out 36.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years and Stryker has increased its dividend for 32 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Stryker beats ResMed on 12 of the 19 factors compared between the two stocks.

How does ResMed compare to Medtronic?

Medtronic (NYSE:MDT) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$36.36B	3.24	$4.80B	$3.73	24.71
ResMed	$5.65B	6.01	$1.52B	$10.43	22.60

Medtronic has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, ResMed has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

In the previous week, Medtronic had 9 more articles in the media than ResMed. MarketBeat recorded 45 mentions for Medtronic and 36 mentions for ResMed. Medtronic's average media sentiment score of 1.36 beat ResMed's score of 1.34 indicating that Medtronic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medtronic	35 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ResMed	28 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.1% of Medtronic shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Comparatively, 0.7% of ResMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ResMed has a net margin of 26.94% compared to Medtronic's net margin of 13.20%. ResMed's return on equity of 25.58% beat Medtronic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medtronic	13.20%	14.51%	7.76%
ResMed	26.94%	25.58%	18.89%

Medtronic presently has a consensus target price of $98.83, indicating a potential upside of 7.24%. ResMed has a consensus target price of $239.38, indicating a potential upside of 1.55%. Given Medtronic's stronger consensus rating and higher possible upside, analysts plainly believe Medtronic is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67
ResMed	0 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.41

Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.1%. ResMed pays an annual dividend of $2.64 per share and has a dividend yield of 1.1%. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ResMed pays out 25.3% of its earnings in the form of a dividend. Medtronic has increased its dividend for 49 consecutive years and ResMed has increased its dividend for 13 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Medtronic beats ResMed on 11 of the 19 factors compared between the two stocks.

Get ResMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RMD vs. The Competition

Export

Metric	ResMed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$34.13B	$5.94B	$7.40B	$24.35B
Dividend Yield	1.12%	1.75%	2.53%	3.70%
P/E Ratio	22.60	21.41	212.23	26.24
Price / Sales	6.01	69.39	630.33	20.88
Price / Cash	18.29	33.21	79.89	33.34
Price / Book	5.16	6.24	13.14	7.69
Net Income	$1.52B	$149.10M	$3.47B	$1.07B
7 Day Performance	2.12%	0.53%	1.38%	-0.21%
1 Month Performance	20.62%	9.26%	8.62%	2.84%
1 Year Performance	-17.38%	6.82%	25.90%	14.58%

ResMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RMD ResMed	4.3898 of 5 stars	$235.73 -0.4%	$239.38 +1.6%	-17.3%	$34.13B	$5.65B	22.60	11,370	Positive News
MEDP Medpace	3.1849 of 5 stars	$597.12 +3.2%	$584.18 -2.2%	+31.5%	$16.15B	$2.53B	35.00	6,200	Trending News Insider Trade
EHC Encompass Health	4.9173 of 5 stars	$121.94 -1.3%	$148.71 +22.0%	-1.6%	$12.19B	$5.94B	19.86	42,000	Trending News Analyst Revision
HIMS Hims & Hers Health	2.3116 of 5 stars	$28.50 +1.2%	$32.43 +13.8%	-26.3%	$6.57B	$2.35B	N/A	2,442	Trending News Analyst Forecast
SYK Stryker	4.9727 of 5 stars	$331.75 -2.2%	$386.28 +16.4%	-15.3%	$130.11B	$25.12B	34.38	56,000	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RMD) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Competitors